Eczema Cream: How to Choose the Right One for Your Skin

The right eczema cream depends on the job it has to do: a fragrance-free moisturizer (an ointment or a ceramide cream) every day to repair the skin barrier, plus an anti-inflammatory cream, usually a topical corticosteroid matched to the body site, when atopic dermatitis flares. The American Academy of Dermatology's 2023 guideline (Sidbury et al.) recommends moisturizers for every patient and supports topical steroids, tacrolimus, pimecrolimus, crisaborole and ruxolitinib cream for active eczema [16].

Why the Right Cream Matters

Eczema (atopic dermatitis) is fundamentally a disease of a broken skin barrier. Genetic variations in filaggrin and other structural proteins leave the epidermis unable to hold moisture and unable to keep irritants, allergens, and microbes out [1]. Every effective eczema treatment strategy starts with restoring that barrier through the right topical products.

Eczema creams do two different jobs. Emollients and moisturizers repair the barrier and are used every day, while anti-inflammatory creams (topical corticosteroids, calcineurin inhibitors, PDE4 inhibitors, JAK inhibitors and tapinarof) calm an active flare. Most people with atopic dermatitis and other forms of eczema need both, in the right order and the right amount.

Which Eczema Cream Should You Use? A Quick Comparison

The right eczema cream is the one matched to your severity, your age and the part of the body affected. Mild dry patches usually respond to a thick moisturizer and short courses of over-the-counter hydrocortisone. Flares on the trunk and limbs usually need a prescription-strength topical corticosteroid, and sensitive areas such as the face and eyelids are often treated with a steroid-free prescription cream.

Ages and approvals in the table come from current FDA labeling; the sections below explain how each class works and where it fits.

Moisturizers: The Foundation

Every eczema patient needs a daily moisturizer, regardless of severity. Moisturizers are not just “nice to have.” Clinical trials have shown that consistent moisturizer use alone reduces flare frequency by 30-50% and decreases the need for topical steroids [2]. Think of moisturizing as the baseline therapy that makes everything else work better.

Ointments

Ointments (petroleum jelly, Aquaphor Healing Ointment) are the most occlusive and effective moisturizers. They contain 80% oil and 20% water, forming a physical barrier that traps moisture in the skin. In clinical comparisons, ointments consistently outperform creams and lotions for barrier repair [2].

The downside is cosmetic: ointments feel greasy and can stain clothing. Most patients find them best suited for nighttime use or for small, severely affected areas. Plain petroleum jelly (Vaseline) is among the most effective and affordable eczema moisturizers available, and it is essentially non-allergenic.

Creams

Creams are the most popular formulation for eczema because they balance efficacy with cosmetic acceptability. They are semi-solid emulsions (roughly 50% oil, 50% water) that absorb well and can be used comfortably during the day [3].

No guideline endorses a particular brand: the American Academy of Dermatology (2023) recommends moisturizers as a category [16]. What matters is the formula. The widely sold creams below are examples of the features to look for, not a ranking:

• CeraVe Moisturizing Cream: An example of a ceramide cream. Contains three essential ceramides (1, 3, 6-II), hyaluronic acid, and uses MVE (multivesicular emulsion) technology for extended release.
• Vanicream Moisturizing Skin Cream: An example of a minimal-ingredient cream. Free of dyes, fragrance, masking fragrance, lanolin, parabens, and formaldehyde releasers, which suits patients with multiple sensitivities.
• Cetaphil Moisturizing Cream: An example of a widely available, well-tolerated basic cream.
• Eucerin Original Healing Cream: An example of a rich formula with a high occlusive content, suited to thick, dry skin.

Lotions

Lotions have the highest water content and lowest oil content, making them the lightest and least occlusive option. They absorb quickly and feel pleasant on the skin but evaporate rapidly, providing less sustained barrier protection. For active eczema, lotions are generally insufficient. They are acceptable for very mild disease or as a secondary, daytime layer in patients who find creams too heavy for certain body areas [2].

Ceramide-Based Products

Ceramides are the dominant lipids in the stratum corneum (outermost skin layer), making up about 50% of the lipid bilayer that holds skin cells together. Eczema skin is deficient in ceramides, and this deficiency directly contributes to barrier dysfunction and transepidermal water loss [4].

Studies show that ceramide-containing moisturizers improve skin hydration, reduce transepidermal water loss, and decrease eczema severity scores compared to conventional moisturizers [5]. Products containing a physiologic ratio of ceramides, cholesterol, and fatty acids (mimicking the skin’s natural composition) perform best.

Colloidal Oatmeal Products

Colloidal oatmeal (finely ground oat particles) has been used for skin conditions for centuries and is FDA-recognized as a skin protectant. It works through multiple mechanisms: anti-inflammatory (via avenanthramides), antioxidant, moisture retention, and pH buffering [6]. Products like Aveeno Eczema Therapy and First Aid Beauty Ultra Repair Cream contain colloidal oatmeal. They are gentle, widely available, and suitable for both children and adults.

What About Natural Oils?

Plant oils are not interchangeable. In a study of adult volunteers, Danby et al. (2013) found that four weeks of olive oil weakened the skin barrier, while sunflower seed oil preserved it [18]. Coconut oil is widely used and generally tolerated, but trials are small. Essential oils such as tea tree and lavender are common contact allergens and are better avoided on eczema skin.

Topical Corticosteroids

When eczema flares and the skin becomes inflamed, itchy, and red, moisturizers alone are not enough. Topical corticosteroids (TCS) are the first-line anti-inflammatory treatment and have been the backbone of eczema management for over 60 years [7].

How They Work

TCS suppress the inflammatory cascade in the skin by inhibiting the release of cytokines, reducing immune cell activation, and constricting blood vessels (which decreases redness and swelling). They are available in seven potency classes in the US system (Class I is the strongest, Class VII the weakest).

Choosing the Right Potency

The single most important principle of topical steroid use: match the potency to the body site [7].

• Face, eyelids, genitals, skin folds: Low potency only. Hydrocortisone 1-2.5% or desonide 0.05%. These areas have thin skin that absorbs steroids rapidly, increasing the risk of atrophy and telangiectasia with stronger formulations.
• Trunk, arms, legs: Medium potency. Triamcinolone acetonide 0.1%, mometasone furoate 0.1%, or fluocinolone acetonide 0.025%.
• Hands, feet, elbows, knees, thick plaques: High to super-high potency. Clobetasol propionate 0.05% or betamethasone dipropionate 0.05%. These areas have thick skin that resists steroid penetration.

Ointment vs. Cream Formulation

Ointment formulations are generally preferred for eczema because they provide better skin penetration and contain fewer preservatives. Cream formulations are better accepted cosmetically and preferred for weeping lesions and skin folds where ointments can be too occlusive [7].

Steroid Safety

Steroid phobia affects up to 80% of eczema patients and caregivers, leading to underapplication and poorly controlled disease [8]. The reality: when used at the right potency for the right body site in appropriate courses (2-4 weeks for flares, with proactive maintenance 2x/week), topical corticosteroids have a well-established safety record. Side effects occur primarily with prolonged, continuous use of inappropriately high-potency steroids on thin-skinned areas [9].

Safety tips:

• Use the lowest effective potency for the body site
• Apply a thin layer (the “fingertip unit” method: one fingertip unit covers an area equivalent to two adult palms)
• Do not use super-potent steroids (clobetasol, halobetasol) for more than 2-4 continuous weeks without provider guidance
• Step down to a lower potency or switch to a steroid-sparing option for maintenance once the flare is controlled
• Apply moisturizer liberally; apply steroid only to actively inflamed areas

What Is Topical Steroid Withdrawal?

Topical steroid withdrawal (TSW), sometimes called red skin syndrome, describes burning, bright redness and skin sensitivity after stopping a topical corticosteroid that was used for a long time. A systematic review by Hajar et al. (2015) found that reported cases mostly involved prolonged daily use of moderate to high potency steroids, often on the face and genitals [19]. The evidence base is made up of case reports and case series, so its true frequency is unknown. Short courses at the potency the body site calls for, followed by a step down rather than an abrupt stop, are the usual way dermatologists reduce the risk.

Proactive “Weekend” Therapy

The proactive approach is one of the most useful changes for patients with frequently relapsing eczema. Instead of waiting for a visible flare and then treating reactively, you apply a mid-potency TCS (or calcineurin inhibitor) to previously affected areas 2 times per week even when the skin looks clear. Clinical trials show this reduces relapse rates by 50-70% compared to reactive treatment alone [10]. The subclinical inflammation that precedes a visible flare is suppressed before it can escalate.

Topical Calcineurin Inhibitors (TCIs)

TCIs are non-steroidal anti-inflammatory creams that work by blocking calcineurin, a protein involved in T-cell activation and cytokine production. They do not cause skin atrophy, making them ideal for long-term use on sensitive areas [11].

Tacrolimus Ointment (Protopic)

• Available in 0.03% (children 2-15) and 0.1% (adults) strengths
• Efficacy comparable to a medium-potency topical corticosteroid
• Ideal for face, eyelids, neck, and genital area where long-term steroid use is risky
• Common side effect: burning and stinging on application, which typically resolves within 3-5 days of regular use. Applying to damp skin and refrigerating the tube can reduce this.
• Excellent for proactive maintenance therapy (applied 2-3x/week)

Pimecrolimus Cream (Elidel)

• Available in 1% strength
• Less potent than tacrolimus, best for mild-to-moderate disease
• Cream vehicle is more cosmetically elegant than tacrolimus ointment
• Less burning/stinging than tacrolimus
• Particularly useful for maintenance therapy in mild facial and flexural eczema

Both TCIs carry an FDA boxed warning about theoretical lymphoma risk, added in 2006 based on animal studies using systemic doses far exceeding topical exposure. Over 15 years of post-marketing surveillance and large epidemiologic studies have not confirmed increased cancer risk with topical use [12]. Major dermatology organizations have called for removal of this warning.

Topical PDE4 Inhibitor: Crisaborole (Eucrisa)

Crisaborole 2% ointment works by inhibiting phosphodiesterase 4 (PDE4), an enzyme that breaks down cyclic AMP (cAMP) in immune cells. By increasing cAMP levels, it dampens the inflammatory response [13].

• Approved for mild-to-moderate atopic dermatitis in patients aged 3 months and older
• Non-steroidal and non-calcineurin inhibitor: a mechanistically distinct option
• Applied twice daily to affected areas
• Efficacy is modest: in clinical trials, 32% of patients achieved clear or almost clear skin at 28 days versus 25% with vehicle (a statistically significant but clinically modest difference)
• Main side effect: application site pain (burning, stinging) in about 4% of patients
• Best role: a gentle, steroid-free option for mild disease or as an additional agent in a rotating treatment strategy to reduce steroid use

Roflumilast Cream (Zoryve)

Roflumilast is a second topical PDE4 inhibitor, applied once daily. The FDA approved roflumilast cream 0.15% for mild to moderate atopic dermatitis in adults and children aged 6 and older in July 2024, and a 0.05% strength for children aged 2 to 5 in October 2025, according to the current FDA prescribing information for roflumilast cream [21]. It was studied in the INTEGUMENT-1 and INTEGUMENT-2 trials. FDA reviewers have described its effect over vehicle as relatively modest, similar to crisaborole, so it suits mild disease and steroid-sparing maintenance rather than severe flares.

Topical JAK Inhibitor: Ruxolitinib (Opzelura)

Ruxolitinib 1.5% cream is the first topical JAK (Janus kinase) inhibitor approved for atopic dermatitis. It blocks JAK1 and JAK2, key signaling molecules in the inflammatory pathway that drives eczema itch and inflammation [14].

• Approved for mild-to-moderate atopic dermatitis in non-immunocompromised patients aged 12 and older in 2021, and extended to children aged 2 and older in September 2025 for disease not adequately controlled by other topical prescription therapies, per the FDA label for ruxolitinib cream [20]
• Applied twice daily to affected areas (up to 20% body surface area, no more than one 60 g tube per week or one 100 g tube per 2 weeks)
• Rapid itch relief: significant itch reduction within 12-36 hours, among the fastest itch responses reported for a topical eczema treatment
• Efficacy: 50-53% of patients achieved IGA 0/1 (clear/almost clear) at 8 weeks versus 15% with vehicle
• No skin atrophy risk
• Carries a boxed warning (class-wide for JAK inhibitors) about serious infections, malignancy, and cardiovascular events, though systemic absorption from topical application is minimal
• Best role: an effective non-steroidal option for facial, eyelid, and sensitive-area eczema, and for patients who want rapid itch control

Tapinarof Cream (Vtama): A Newer Steroid-Free Option

Tapinarof 1% cream is an aryl hydrocarbon receptor (AhR) agonist, a mechanism different from every other eczema cream on this page. It is applied once daily. First approved for plaque psoriasis in 2022, it gained FDA approval for atopic dermatitis in adults and children aged 2 and older in December 2024, according to the FDA prescribing information for tapinarof cream [22].

The approval rested on the ADORING 1 and ADORING 2 trials. The most common side effects listed on the label are upper respiratory tract infection, folliculitis (small bumps around hair follicles) and headache. Tapinarof carries no boxed warning. It is newer than the other options, so long-term real-world data are still building, and insurance plans often ask for a trial of older creams first.

OTC vs. Prescription: When Do You Need to Step Up?

Over-the-counter (OTC) eczema creams are enough for many people with mild, localized atopic dermatitis. A prescription cream becomes the next step when OTC products stop working, when the rash spreads, or when it sits on skin where stronger steroids are risky. The stepwise approach below follows the American Academy of Dermatology topical therapy guidelines [7][16].

• Start with OTC moisturizers (ceramide cream, petroleum jelly, colloidal oatmeal lotion) and OTC hydrocortisone 1% for mild flares. This is sufficient for many patients with mild, localized eczema.
• Move to prescription topicals when OTC products do not control symptoms within 2-3 weeks, when eczema covers more than small areas, when it affects the face or eyelids (where calcineurin inhibitors are preferred), or when flares recur as soon as treatment stops.
• Consider systemic therapy when prescription topicals at appropriate potency, used consistently and correctly, do not adequately control the disease, or when eczema covers a large body surface area that makes topical treatment impractical.

Choosing an Eczema Cream by Body Area and Age

The same eczema cream is not right for every part of the body. Thin skin absorbs more medicine, and infants and young children have more skin surface for their weight, so dermatologists pick gentler options for the face, skin folds and babies.

Eczema Cream for the Face and Eyelids

Facial and eyelid eczema is usually treated with a low-potency steroid such as hydrocortisone 1% to 2.5% for short courses, or with a steroid-free cream such as tacrolimus, pimecrolimus, crisaborole or ruxolitinib for longer use [7]. A thin, fragrance-free ceramide cream works well as the daily moisturizer. More detail on triggers and skincare is in the guide to eczema on the face.

Eczema Cream for the Hands

Hand eczema needs a stronger approach because palm skin is thick and the hands are washed many times a day. A medium to high potency steroid ointment for flares, an ointment moisturizer after every wash and cotton-lined gloves for wet work are the usual starting points. Blistering hand eczema is covered in the guide to dyshidrotic eczema (pompholyx).

Eczema Cream for Babies and Children

For infants, the foundation is a plain, fragrance-free ointment or cream applied at least twice a day, with low-potency hydrocortisone for flares under a pediatrician's guidance. Crisaborole is FDA labeled from 3 months of age, tacrolimus 0.03% and pimecrolimus from age 2, and ruxolitinib and tapinarof from age 2 [20][22]. The guide to eczema in babies covers bathing and daily care.

Application Tips That Make a Real Difference

How you apply your eczema cream is almost as important as which cream you choose. These evidence-based techniques improve outcomes [3]:

1. Bathe or shower in lukewarm water for 5 to 10 minutes and pat the skin until it is damp, not dry.
2. Apply any prescription anti-inflammatory cream to the inflamed patches only.
3. Apply moisturizer generously everywhere else within 3 minutes.
4. Repeat the moisturizer at least once more during the day, and after handwashing for hand eczema.

Timing

Apply moisturizer within 3 minutes of bathing while skin is still damp (“soak and seal”). This traps water in the skin and improves hydration more effectively than applying to dry skin.

Amount

Most patients dramatically underuse their moisturizers. Clinical guidelines recommend 250 g per week for a child and 500 g per week for an adult for full-body application. The “fingertip unit” system provides guidance: one fingertip unit (a strip of cream from the tip of the index finger to the first crease) covers an area approximately equal to two adult palms [7].

Order of Application

When using both a moisturizer and a topical steroid, apply the steroid to inflamed areas and moisturizer everywhere. Some guidelines suggest order does not matter, as the steroid penetrates regardless [15]. The key point is to use both consistently.

Direction and Storage

Apply creams in the direction of hair growth to avoid folliculitis. Some patients find that refrigerating their moisturizer provides additional soothing benefit through activation of cold receptors in the skin.

Ingredients to Avoid in Eczema Products

For eczema-prone skin, avoid products containing [3]:

• Fragrance (including “natural” fragrance, essential oils, and parfum)
• Dyes and colorants
• Sodium lauryl sulfate (SLS)
• Alcohol (denatured alcohol, SD alcohol) in leave-on products
• Methylisothiazolinone (MI) and other sensitizing preservatives
• Lanolin (wool alcohol): a relatively common contact allergen in eczema patients, though pure medical-grade lanolin has lower sensitization rates
• Propylene glycol: can sting and irritate compromised skin

Reading ingredient labels is a necessary skill for eczema patients. The National Eczema Association’s “Seal of Acceptance” program certifies products suitable for sensitive and eczema-prone skin.

A cream that stings for a few seconds on broken skin is common, but a rash that worsens where a product is applied can be allergic contact dermatitis to one of its ingredients. Dermatologists confirm this with patch testing, which identifies the specific allergen to avoid.

When Eczema Creams Are Not Enough

Moderate to severe atopic dermatitis that does not respond to well-used prescription creams is treated with phototherapy or systemic medicines. These include the injectable biologics dupilumab (Dupixent), tralokinumab (Adbry) and lebrikizumab (Ebglyss), oral JAK inhibitors such as upadacitinib and abrocitinib, and older immunosuppressants such as cyclosporine and methotrexate. In the SOLO 1 and SOLO 2 trials (Simpson et al., 2016), dupilumab was tested on top of daily moisturizers, and moisturizing stays part of care on every systemic treatment [17]. The full ladder is laid out in the guide to eczema treatment options and in the eczema treatment overview.

Board-certified dermatologists and allergists manage most stubborn eczema, and some integrative and functional medicine clinics also see patients with chronic skin disease. Many of those clinics offer diet, gut health or supplement programs that are cash pay and have limited trial evidence for eczema, so ask what each clinic offers alongside standard care. To compare providers, browse clinics that list eczema treatment across the US. Listing order on Regenerated.com is not paid ranking, Featured slots are labeled and capped, Verified means a clinic has completed credential checks rather than paid for placement, and the directory is free for patients. Inclusion in the directory is not an endorsement.

Frequently Asked Questions About Eczema Cream

What is the best cream for eczema?

No single cream suits everyone with eczema. Daily care starts with a fragrance-free ointment such as petroleum jelly or a ceramide cream, which the American Academy of Dermatology (2023) recommends for every patient. Active flares need an anti-inflammatory cream: a topical corticosteroid matched to the body site, or a steroid-free option such as tacrolimus, pimecrolimus, crisaborole, roflumilast, ruxolitinib or tapinarof. The right choice depends on severity, age and where the rash sits.

Is hydrocortisone cream good for eczema?

Over-the-counter hydrocortisone 1% is a reasonable first step for small, mild eczema flares in adults and older children. It is a low-potency steroid, so it is gentle enough for short courses on the face and skin folds but often too weak for thick patches on the hands, feet or limbs. If a flare has not improved after about 2 to 3 weeks of regular use, a clinician can prescribe a stronger or steroid-free cream.

Can I use eczema cream on my face?

Yes, with the right product. Facial skin is thin and absorbs steroids readily, so guidelines limit the face to low-potency steroids such as hydrocortisone or desonide for short courses. For longer use, dermatologists often prefer steroid-free creams such as tacrolimus, pimecrolimus or ruxolitinib, which do not thin the skin. Avoid medium and high potency steroids on the eyelids unless a clinician has prescribed them for a defined period.

How long does it take for eczema cream to work?

Moisturizers ease dryness within days, but their flare-preventing effect builds over weeks of twice-daily use. Topical corticosteroids usually calm redness and itch within a few days to two weeks. In its phase 3 trials, ruxolitinib cream reduced itch within 12 to 36 hours, while crisaborole and roflumilast work more gradually. A flare that has not improved within 2 to 3 weeks of correct use deserves a review with a clinician.

Is cream or ointment better for eczema?

Ointments are usually better for eczema because their high oil content seals in water most effectively and they contain fewer preservatives that can sting. Creams absorb faster and feel lighter, so many people use a cream during the day and an ointment at night. For medicated products, ointments suit dry, thick patches, while creams suit weeping eczema and skin folds where an ointment can feel too heavy.

Do I need a prescription eczema cream?

Many people with mild eczema manage well with over-the-counter moisturizers and short courses of hydrocortisone 1%. A prescription cream is the next step when flares last more than 2 to 3 weeks, cover larger areas, affect the face or eyelids, or return as soon as treatment stops. Primary care clinicians, pediatricians and dermatologists can all prescribe stronger steroids and steroid-free creams such as tacrolimus or ruxolitinib.

Related Reading

• Eczema: Complete Guide
• Eczema Treatment: Steroids, Biologics, Natural Options
• Eczema on Face: Causes, Gentle Treatments, and Skincare Tips
• Eczema on Hands: Causes, Types, and Treatment

Sources

1. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446. doi:10.1038/ng1767 ↩
2. van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2(2):CD012119. doi:10.1002/14651858.CD012119.pub2 ↩
3. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi:10.1111/jdv.14891 ↩
4. Imokawa G, Abe A, Jin K, et al. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol. 1991;96(4):523-526. doi:10.1111/1523-1747.ep12470233 ↩
5. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47(2):198-208. doi:10.1067/mjd.2002.124617 ↩
6. Reynertson KA, Garay M, Nebus J, et al. Anti-inflammatory activities of colloidal oatmeal (Avena sativa) contribute to the effectiveness of oats in treatment of itch associated with dry, irritated skin. J Drugs Dermatol. 2015;14(1):43-48. ↩
7. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi:10.1016/j.jaad.2014.03.023 ↩
8. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931-936. doi:10.1046/j.1365-2133.2000.03473.x ↩
9. Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15. doi:10.1016/j.jaad.2005.01.010 ↩
10. Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63(6):742-750. doi:10.1111/j.1398-9995.2008.01683.x ↩
11. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002;109(3):547-555. doi:10.1067/mai.2002.121832 ↩
12. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808-816. doi:10.1038/sj.jid.5700622 ↩
13. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503. doi:10.1016/j.jaad.2016.05.046 ↩
14. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863-872. doi:10.1016/j.jaad.2021.04.085 ↩
15. Siegfried EC, Jaworski JC, Kaiser JD, et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75. doi:10.1186/s12887-016-0607-9 ↩
16. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1-e20. doi:10.1016/j.jaad.2022.12.029 ↩
17. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348. doi:10.1056/NEJMoa1610020 ↩
18. Danby SG, AlEnezi T, Sultan A, et al. Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care. Pediatr Dermatol. 2013;30(1):42-50. doi:10.1111/j.1525-1470.2012.01865.x ↩
19. Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541-549. doi:10.1016/j.jaad.2014.11.024 ↩
20. US Food and Drug Administration. OPZELURA (ruxolitinib) cream, prescribing information, revised 2025 (NDA 215309/S-007). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215309s007lbl.pdf ↩
21. US Food and Drug Administration. ZORYVE (roflumilast) cream 0.3%, 0.15%, 0.05%, prescribing information, revised 2026 (NDA 215985). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215985s015sdn642lbl.pdf ↩
22. US Food and Drug Administration. VTAMA (tapinarof) cream 1%, prescribing information, revised December 2024 (NDA 215272). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215272s002lbl.pdf ↩